索菲亚·林德奎斯特
媒体与财经传播经理
Email: sofia.lindqvist@molnlycke.com
Phone: +4672 255 35 09
瑞典哥德堡。2025 年 4 月 1 日。今天,Mölnlycke Health Care 发布了 2024 年年度报告,包括可持续发展报告。
“我们强劲的财务状况和持续增长使我们能够指导我们的未来和持续的投资。与此同时,很明显,我们的战略和以前的投资已经得到了回报,与我们的客户建立了密切的关系,与他们并肩作战,以应对当今医疗保健的挑战,“Mölnlycke 首席执行官 Zlatko Rihter 说。
本年度亮点:
下载并阅读 www.molnlycke.com/corporate/about/reports 的完整报告
欲了解更多信息,请联系:
媒体与财经传播经理
Email: sofia.lindqvist@molnlycke.com
Phone: +4672 255 35 09
Mölnlycke Health Care, a world leading MedTech company, has expanded its commitment to operations in the Middle East by extending its stake from 33.3% to 60% to become majority shareholder in Tamer Mölnlycke Care - a joint venture with Tamer Group, the market leader in healthcare distribution in the Kingdom of Saudi Arabia.
Mölnlycke signed an agreement to acquire P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturizing.
On 28 April 2023, Mölnlycke entered into a new EUR 350 million multicurrency revolving credit facility. The facility has a tenor of five years with two one-year extension options and will be used as a backup for general corporate purposes. The facility is a refinancing of the existing and undrawn revolving credit facility signed in 2017.
Mölnlycke Health Care’s Wound Care business area is delighted to announce the launch of its 2025 Future Summit, an educational event bringing together healthcare professionals (HCPs) from across Europe, the Middle East, and Africa (EMEA).
Mölnlycke is proud to announce that it has been awarded the Capgemini Swedish Sustainability Tech Award 2024 for Mölnlycke ProcedurePak® trays. This accolade recognises the company’s innovative practices and dedication to revolutionise healthcare for people and planet.
Joucla’s extensive experience and insights to drive financial strategy and growth initiatives.
The centre is expected to serve 10,000 patients in the region with transformative cleft care in the first three years of operations.